- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00955461
Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System
November 27, 2012 updated by: ConBio, a Cynosure Company
Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation
The purpose of this study is to compare the results of treatment between the side of the face treated with the RevLite Laser and the side of the face treated with a fractionated laser system.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10075
- Sadick Research Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Fitzpatrick Skin Type I-VI and Wrinkle Class I
- Between the ages of 25-65
- Evidence of bilateral dyschromia
Exclusion Criteria:
- Pregnant, lactating, or is planning to become pregnant
- history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
- any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical or systemic therapy
- coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
- any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study
- currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days
- unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
- unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
- Accutane within 6 months
- need to be exposed to artificial tanning devices or excessive sunlight during the trial
- prior treatment with parenteral gold therapy
- Diabetes Type 1 or 2
- does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
- artificial tanning within 1 month
- (micro)dermabrasion within 3 months
- other laser or IPL to the face within 6 months
- chemical peel within 1 month
- injectable fillers within 3 months
- topical retinoids within 3 months
- over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic acid, or agents specifically advertised as having anti-aging or age-inhibiting properties) within 1 month
- history of keloids or hypertrophic scarring
- evidence of compromised wound healing
- history of cold sores, chickenpox or shingles and unwilling to take a prophylactic course of Valtrex/acyclovir
- allergy to acyclovir
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Laser treatment
Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
|
Electro-optic Q-Switched Nd: YAG Laser treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of the percentage of overall, cumulative improvement from Baseline in the appearance of wrinkles, skin tone and/or texture, pigmentation and acne scars
Time Frame: 3 and 6 months post final treatment
|
3 and 6 months post final treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Neil Sadick, MD, Sadick Research Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
August 7, 2009
First Posted (Estimate)
August 10, 2009
Study Record Updates
Last Update Posted (Estimate)
November 28, 2012
Last Update Submitted That Met QC Criteria
November 27, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- C66-07-F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Scars
-
Ulthera, IncCompleted
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Northwestern UniversityActive, not recruiting
-
Massachusetts General HospitalUnknown
-
Goldman, Butterwick, Fitzpatrick and GroffCynosure, LLCNot yet recruitingAcne Scars
-
Cynosure, Inc.Completed
-
Massachusetts General HospitalAmerican Society for Dermatologic SurgeryCompleted
-
Dongtan Sacred Heart HospitalUnknownAcne ScarsKorea, Republic of
-
Skincare Physicians of Chestnut HillCandela CorporationCompletedAcne Scars | AcneUnited States
-
Alma Lasers Inc.CompletedAcne Scars | WrinklesUnited States
Clinical Trials on RevLite laser treatment
-
Cynosure, Inc.Terminated
-
Cynosure, Inc.CompletedFacial Solar LentiginesUnited States
-
Cynosure, Inc.CompletedUnwanted TattoosUnited States
-
ConBio, a Cynosure CompanyCompleted
-
University Hospital, GhentCompleted
-
Sun Yat-sen UniversityUnknownDiabetic Macular EdemaChina
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Candela CorporationCompleted
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
William Beaumont HospitalsWithdrawnUrinary Incontinence | Stress Urinary IncontinenceUnited States
-
University of Texas Southwestern Medical CenterTerminated